COMBINATION OF HDA INHIBITOR AND ANTIMETABOLITE

摘要

FIELD: medicine.SUBSTANCE: what is used is a histon deacetylase inhibitor N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide or its pharmaceutically acceptable salt and antimetabolite 5-azacytidine.EFFECT: method enables suppressing the development or providing the higher clinical effectiveness of myelodysplastic syndrome and acute myeloblastic leucosis.1 tbl, 2 ex, 2 dwg